PI2 Stock Chart & Stats
€0.02
<€0.01(3.57%)
At close: 4:00 PM EST
€0.02
<€0.01(3.57%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.04
Previous CloseN/A
Volume0.00
Average Volume (3M)326.00
Market Cap
€5.97M
Enterprise Value€20.50
Total Cash (Recent Filing)€1.10M
Total Debt (Recent Filing)€15.95M
Price to Earnings (P/E)―
Beta-4.82
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding350,724,900
10 Day Avg. Volume380
30 Day Avg. Volume326
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)-0.77
Price to Sales (P/S)1.96
P/FCF Ratio-51.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialized Proteomics ServicesThe company operates in a specialized proteomics market and delivers complex analytical workflows that support biomedical research and drug development. Serving pharmaceutical, biotechnology, and academic customers gives the business several end markets and a service offering aligned with ongoing demand for outsourced research capabilities.
Improved Cash FlowAlthough cash generation remains negative, the substantial improvement from 2024 indicates better short-term cash management and reduced operating burn. If sustained, this could lessen funding pressure, improve the company’s ability to support laboratory operations, and provide a stronger base for stabilizing the business.
Proprietary Technology PlatformIts history of developing proprietary reagents, software, and biomarker programs provides potential differentiation beyond fee-for-service work. These assets could support higher-value research collaborations, licensing opportunities, or product commercialization if the company secures sufficient funding and partnerships.
Bears Say
Falling Revenue And LossesDeclining revenue combined with negative gross profit and widening operating and net losses indicates weak cost absorption and limited earnings stability. Persistent losses can constrain investment in laboratory capabilities, reduce strategic flexibility, and make a durable recovery dependent on renewed demand or additional financing.
Strained Balance SheetRising debt alongside deeply negative equity leaves the capital structure under substantial strain and limits financial flexibility. The imbalance between assets and debt increases refinancing and dilution risk, while servicing obligations may restrict the resources available for growth, research, or operational recovery.
Limited Self-Funding CapacityFree cash flow is still negative despite recent improvement, so the company is not yet consistently funding operations and investment internally. Volatile historical cash generation makes planning more difficult and increases reliance on external capital or improved operating performance to sustain the business.
Proteome Sciences News
PI2 FAQ
What was Proteome Sciences PLC’s price range in the past 12 months?
Proteome Sciences PLC lowest stock price was <€0.01 and its highest was €0.04 in the past 12 months.
What is Proteome Sciences PLC’s market cap?
Proteome Sciences PLC’s market cap is €5.97M.
When is Proteome Sciences PLC’s upcoming earnings report date?
Proteome Sciences PLC’s upcoming earnings report date is Apr 01, 2027 which is in 181 days.
How were Proteome Sciences PLC’s earnings last quarter?
Proteome Sciences PLC released its earnings results on Jul 23, 2026. The company reported -€0.005 earnings per share for the quarter.
Is Proteome Sciences PLC overvalued?
According to Wall Street analysts Proteome Sciences PLC’s price is currently Overvalued.
Does Proteome Sciences PLC pay dividends?
Proteome Sciences PLC does not currently pay dividends.
What is Proteome Sciences PLC’s EPS estimate?
Proteome Sciences PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Proteome Sciences PLC have?
Proteome Sciences PLC has 350,724,900 shares outstanding.
What happened to Proteome Sciences PLC’s price movement after its last earnings report?
Proteome Sciences PLC reported an EPS of -€0.005 in its last earnings report. Following the earnings report the stock price went down -7.143%.
Which hedge fund is a major shareholder of Proteome Sciences PLC?
Currently, no hedge funds are holding shares in DE:PI2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Proteome Sciences PLC
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant that provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator which analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids. It also offers top 14 and top 65 super depletion of proteins from serum and plasma; selective reaction monitoring (SRM) and parallel reaction monitoring (PRM) based biomarker assay development; SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers; and TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates. The company serves its products to pharmaceutical and biotechnology companies, as well as to academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.